Mini-Review: The Complete Guide to Gut Peptides That Control How Full You Feel

The gastrointestinal tract and pancreas release at least 8 hormones regulating satiety and body weight, with GLP-1, PYY, and amylin showing the most therapeutic promise for obesity treatment.

Druce, Maralyn R et al.·Endocrinology·2004·Moderate EvidenceReview
RPEP-00906ReviewModerate Evidence2004RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
Not reported

What This Study Found

At least 8 gut/pancreatic hormones regulate satiety, with GLP-1, PYY, and amylin identified as the most promising therapeutic targets for obesity — with combination therapy suggested for superior outcomes.

Key Numbers

How They Did This

Mini-review of gut peptide satiety regulation covering ghrelin, GLP-1, oxyntomodulin, PYY, CCK, amylin, PP, and bombesin/GRP.

Why This Research Matters

This review identified GLP-1 as a top therapeutic target years before semaglutide's success. It also predicted combination peptide therapy — validated by tirzepatide (GLP-1/GIP dual agonist).

The Bigger Picture

The gut is the body's largest endocrine organ for appetite control. This review mapped the complete satiety peptide landscape that modern obesity drugs now target.

What This Study Doesn't Tell Us

Brief review from 2004. The therapeutic hierarchy has shifted since (GLP-1 became dominant). Combination therapy details were speculative.

Questions This Raises

  • ?Will triple-peptide combinations outperform dual agonists?
  • ?Which combination of satiety signals produces the best weight loss with fewest side effects?
  • ?Can the gut peptide profile predict which obesity drug will work best for each patient?

Trust & Context

Key Stat:
GLP-1 predicted This 2004 review identified GLP-1 as having the most therapeutic promise for obesity — validated over a decade later by semaglutide's blockbuster success
Evidence Grade:
Moderate evidence from a concise review synthesizing the gut peptide satiety landscape.
Study Age:
Published in 2004. This review's prediction that GLP-1 would be the top obesity target was dramatically validated by semaglutide/tirzepatide.
Original Title:
Minireview: Gut peptides regulating satiety.
Published In:
Endocrinology, 145(6), 2660-5 (2004)
Database ID:
RPEP-00906

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

How many hormones control appetite?

At least 8 from the gut and pancreas alone, plus brain peptides. Ghrelin makes you hungry; GLP-1, PYY, CCK, and others make you full. It's a remarkably complex system.

Did this review predict Ozempic?

In a sense, yes — it identified GLP-1 as having the most therapeutic promise for obesity in 2004, more than 15 years before semaglutide (Ozempic/Wegovy) became one of the most impactful drugs in medicine.

Read More on RethinkPeptides

Cite This Study

RPEP-00906·https://rethinkpeptides.com/research/RPEP-00906

APA

Druce, Maralyn R; Small, Caroline J; Bloom, Stephen R. (2004). Minireview: Gut peptides regulating satiety.. Endocrinology, 145(6), 2660-5.

MLA

Druce, Maralyn R, et al. "Minireview: Gut peptides regulating satiety.." Endocrinology, 2004.

RethinkPeptides

RethinkPeptides Research Database. "Minireview: Gut peptides regulating satiety." RPEP-00906. Retrieved from https://rethinkpeptides.com/research/druce-2004-minireview-gut-peptides-regulating

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.